Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review ; volume:38 ; number:2 ; day:11 ; month:1 ; year:2021 ; pages:969-993 ; date:2.2021
Advances in therapy ; 38, Heft 2 (11.1.2021), 969-993, 2.2021
- Urheber
-
Cella, David
Evans, Jennifer
Feuilly, Marion
Neggers, Sebastian
Genechten, Dirk Van
Herman, Jackie
Khan, Mohid S.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-020-01600-x
- URN
-
urn:nbn:de:101:1-2021040702381000669516
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cella, David
- Evans, Jennifer
- Feuilly, Marion
- Neggers, Sebastian
- Genechten, Dirk Van
- Herman, Jackie
- Khan, Mohid S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management
Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
The Coordination Abilities of New Cyclic Analogs of Somatostatin
A case of malignant insulinoma responsive to somatostatin analogs treatment
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management
Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
The Coordination Abilities of New Cyclic Analogs of Somatostatin
A case of malignant insulinoma responsive to somatostatin analogs treatment
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management
Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
The Coordination Abilities of New Cyclic Analogs of Somatostatin
A case of malignant insulinoma responsive to somatostatin analogs treatment